巨细胞性关节炎的当前前前景:我们能否更好地将病原和治疗联系起来?
Daniela Opriș-Belinski1,2, Claudia Oana Cobilinschi1,2, Ioana Săulescu1,2
1Department of Rheumatology and Internal Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Medicina (Kaunas, Lithuania)
|March 28, 2024
概括
巨细胞动脉炎 (GCA) 是一种影响老年人的大血管血管炎. 目前的治疗重点是葡萄糖皮质类药物,但新疗法,如阿巴巴塞普和JAK抑制剂显示出更好的管理的希望.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 血管医学 血管医学
背景情况:
- 巨细胞动脉炎 (GCA) 是一种严重的大血管血管炎,主要影响老年人.
- 它向大动脉及其分支,导致骨和外症状,包括视力丧失.
- 病理生理学涉及颗粒状炎症导致缺血性并发症.
研究的目的:
- 审查目前GCA的治疗策略,重点关注葡萄糖皮质类药物 (GCs) 和新兴疗法.
- 讨论优化GC剂量和逐渐缩小的挑战.
- 探索新的治疗点和GCA管理的药物.
主要方法:
- 对现有关于GCA病理生理学和治疗的文献的审查.
- 对当前临床指导方针的分析和对GCA疗法的研究.
- 讨论新兴治疗剂及其机制.
主要成果:
- 葡萄糖皮质类药物 (GCs) 仍然是GCA治疗活跃病变和炎症的基石.
- 甲托雷克萨特和托西利祖马布是已知的皮质类固醇节约剂,可以减少GC负担和复发率.
- 包括阿巴塔塞普特,雅努斯激酶 (JAK) 抑制剂和GM-CSF受体抑制剂在内的新药显示出潜在的.
结论:
- 最佳的GC剂量和GC的逐渐减少需要进一步的研究.
- 已建立的类固醇节约剂,如美托特雷克萨特和托西利祖马布,可以改善患者的治疗结果.
- 新兴疗法为GCA治疗提供了有前途的未来方向,有可能提高疗效并降低GC毒性.
相关概念视频
Connective Tissue Cell Types
3.2K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.2K
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


